

Product Update:

tiotropium/olodaterol 2.5 microgram/ 2.5 microgram inhalation solution
(Spiolto[®] Respimat[®]) SMC No. (1099/15)
Boehringer Ingelheim Ltd

9 October 2015

The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in Scotland. The advice is summarised as follows:

ADVICE: following an abbreviated submission

tiotropium/olodaterol (Spiolto[®] Respimat[®]) is accepted for use within NHS Scotland.

Indication under review: maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD).

Spiolto[®] Respimat[®] should be used in patients for whom tiotropium and olodaterol are appropriate choices of antimuscarinic and long-acting beta₂-agonist respectively.

Tiotropium/olodaterol (Spiolto[®] Respimat[®]) is available at a lower cost than the individual inhalers given separately.

Advice context:

No part of this advice may be used without the whole of the advice being quoted in full.

This advice represents the view of the Scottish Medicines Consortium and was arrived at after evaluation of the evidence submitted by the company. It is provided to inform the considerations of Area Drug & Therapeutics Committees and NHS Boards in Scotland in determining medicines for local use or local formulary inclusion. This advice does not override the individual responsibility of health professionals to make decisions in the exercise of their clinical judgement in the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.

This assessment is based on data submitted by the applicant company up to and including 07 August 2015.

Chairman
Scottish Medicines Consortium